Two big IFs
1. IF PGEN is able to dose AAV gene therapy relapsers and redose them as necessary; and
2. IF PGEN is able to capture a number of monogenic and polygenic diseases including hemophilia
a price target of $31 is very low. Then add current pipeline to that.